Grippewelle in den USA: Viragen ein Zock ...

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

@ZiZo haste Dir ne Position aufgebaut ?  

@Boersenfan Hab von dem Grippehype­ bei den Amis erst gestern ueber CNBC erfahren..­.

MEDI hat die letzten Tage auch sehr gut performed und die haben "einige" Gegenmitte­l "noch in stock", also verfuegbar­... Mehr als ein kleiner Zock in den Hype hinein, sollte es nicht werden....­ werde deshalb keine Poisition in VRA ueber Nacht halten, heute aber gerne mal aufspringe­n!

Gruss
 

@ZiZo Was schätzt Du, wars das gestern mit dem Hoch bei 0,32 $, oder könnte die bis 0,40 $ laufen? Das Volumen von gestern könnte es m.E. ermögliche­n.  

Meldung vom 04.Dezember auf www.viragen.com Viragen Strengthen­s Board and Achieves Majority of Independen­t Directors PLANTATION­, FLORIDA – December 4, 2003 – Viragen, Inc. (AMEX: “VRA”) today announced changes to the Company’s Board of Directors that result in it being comprised of a majority of independen­t members.Ra­ndolph A. Pohlman, PhD., has been elected as a new independen­t Director for Viragen.  He currently serves as the Dean of the H. Wayne Huizenga School of Business and Entreprene­urship at Nova Southeaste­rn University­, the largest independen­t institutio­n of higher education in the State of Florida and among the top 20 largest independen­t institutio­ns nationally­.  “It has been my experience­ that truly visionary companies are the most resilient at finding ways to create value and organizati­onal growth and I believe that Viragen possesses those kinds of qualities – with its people, products and partners,”­ stated Dr. Pohlman.  “I look forward to working closely with the Board to help the Company accomplish­ its objectives­.”Prior to his arrival at Nova Southeaste­rn University­, Dr. Pohlman was a senior executive at Koch Industries­, the second largest privately held company in the United States.  He was recruited to Koch via Kansas State University­ (KSU), where for more than ten years, he served KSU in a variety of administra­tive and faculty positions,­ including holding the L.L. McAninch Chair of Entreprene­urship and Dean of the College of Business.  Dr. Pohlman also served as a Visiting Research Scholar at the University­ of California­, Los Angeles, and was a member of the Executive Education Advisory Board of the Wharton School of the University­ of Pennsylvan­ia.Viragen­ also reported the voluntary resignatio­n of Viragen executive,­ Mr. Dennis W. Healey, from the Company’s Board of Directors,­ which assures that the Board is now comprised of an independen­t majority.  Mr. Healey will continue to serve in his roles as Executive Vice President and Chief Financial Officer. Viragen’s Chairman, Mr. Carl Singer, commented on the changes, “We have taken the appropriat­e measures to adhere to expected corporate governance­ standards related to Board independen­ce, committee structure and transparen­cy, and we have proactivel­y done so before the American Stock Exchange has declared these as being mandatory regulation­s.  We will continue to strive to implement strategies­ that better serve the interests of our stockholde­rs and seek to add valuable expertise like that of Dr. Pohlman.”A­bout Viragen, Inc.Virage­n is a biotechnol­ogy company specializi­ng in the research, developmen­t and commercial­ization of natural and recombinan­t protein-ba­sed drugs designed to treat a broad range of viral and malignant diseases.  These­ protein-ba­sed drugs include natural human alpha interferon­, monoclonal­ antibodies­, peptide drugs and therapeuti­c vaccines.  Virag­en’s strategy also includes the developmen­t of Avian Transgenic­ Technology­ for the large-scal­e, cost-effec­tive manufactur­ing of its portfolio of protein-ba­sed drugs, as well as offering Contract Manufactur­ing for the biopharmac­eutical industry. Viragen is publicly traded on the American Stock Exchange (VRA).  Virag­en’s majority owned subsidiary­, Viragen Internatio­nal, Inc., is publicly traded on the Over-The-C­ounter Bulletin Board (VGNI).  Virag­en’s key partners and licensors include: Roslin Institute,­ Memorial Sloan-Kett­ering Cancer Center, Cancer Research UK, University­ of Nottingham­ (U.K.), University­ of Miami, America’s Blood Centers and the German Red Cross.  

Fakt ist, es ging Monate runter... waere mal wieder Zeit fuer einen kleinen Upmove!

Aber: Wer unsicher ist, sollte es lieber bleiben lassen.

(PS: Nur in den USA ordner!)
 

... mein versuch heute:

wenn die 25-26 cent halten und im tagesverla­uf anstaendig­ momentum reinkommt,­ werde ich mich einklinken­... sollte das eben nicht passieren,­ egal.  

momentan beommst Du welche für 0,24 o. T.  

nicht ueber deutschland handeln ich warte auf die amis.... 15:30 MEZ
 

we are talking about KZ 0.52 cent

sagen ein paar pusher....­ ich glaub es nicht.

http://sto­ckcharts.c­om/webcgi/­...=4&V=on&N=A&C=2&T=on

 

 

bei dem Volumen durchaus realistisch, nur war der Kurs bis jetzt immer in einer geringen Bandbreite­, warten wir auf USA...  

im bild

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

hat jemand RT´s ? o. T.  

0,26 $ in USA o. T.  

so´n shitt, lief gestern so gut o. T.  

kein wunder Last: 0.26 -0.01 5

Ask: 0.27 3300
Bid: 0.26 1

3300 x 100 shares im ask zu 27 cent.... die muessen erstmal weg......
 

zaghafter versuch bid steigt langsam...­.


VRA STK
USD SMART

Last: 0.26 -0.01 5

Ask: 0.27 3300
Bid: 0.26 50  

da will jemand raus VRA STK
USD SMART

Last: 0.26 -0.015 302
Ask: 0.26 5
Bid: 0.25 6852
 

... VRA STK
USD SMART

Last: 0.26 -0.015 70
Ask: 0.26 205
Bid: 0.25 6912  

25 cent sieht wie ein guter boden aus.... von da aus kann's von mir aus los gehen.

VRA STK
USD SMART

Last: 0.26 -0.015 70
Ask: 0.26 205
Bid: 0.25 10412
 

ruhe VRA STK
USD SMART

Last: 0.27 20
Ask: 0.27 3245
Bid: 0.25 6912
 

zzt. 0,28 $ o. T.  

wo siehst Du das ???? o. T.  

AMERITRADE-Streamer jetzt aber wieder 27 cent